Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Change in Cash (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Change in Cash for 4 consecutive years, with -$2.4 million as the latest value for Q4 2024.

  • Quarterly Change in Cash rose 25.05% to -$2.4 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$9.4 million through Dec 2024, up 43.85% year-over-year, with the annual reading at $48.3 million for FY2025, 613.77% up from the prior year.
  • Change in Cash hit -$2.4 million in Q4 2024 for Pasithea Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $32.4 million in Q4 2021 to a low of -$9.3 million in Q4 2022.
  • Historically, Change in Cash has averaged $421488.9 across 4 years, with a median of -$2.9 million in 2022.
  • Biggest five-year swings in Change in Cash: tumbled 423.6% in 2022 and later surged 119.73% in 2024.
  • Year by year, Change in Cash stood at $32.4 million in 2021, then crashed by 128.68% to -$9.3 million in 2022, then surged by 64.98% to -$3.3 million in 2023, then rose by 25.05% to -$2.4 million in 2024.
  • Business Quant data shows Change in Cash for KTTA at -$2.4 million in Q4 2024, $1.4 million in Q3 2024, and -$4.0 million in Q2 2024.